Mesoblast Limited (MESO)
NASDAQ: MESO
· Real-Time Price · USD
10.68
-0.18 (-1.66%)
At close: Jul 03, 2025, 3:16 PM
10.98
2.81%
After-hours: Jul 03, 2025, 04:15 PM EDT
-1.66% (1D)
| Bid | 10.6 |
| Market Cap | 1.36B |
| Revenue (ttm) | 5.67M |
| Net Income (ttm) | -103.35M |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -12 |
| Forward PE | -31.9 |
| Analyst | Buy |
| Ask | 11.19 |
| Volume | 208,695 |
| Avg. Volume (20D) | 214,714 |
| Open | 10.72 |
| Previous Close | 10.86 |
| Day's Range | 10.56 - 10.81 |
| 52-Week Range | 5.78 - 22.00 |
| Beta | 1.42 |
About MESO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MESO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MESO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
+11.29%
Mesoblast shares are trading higher after the comp...
Unlock content with
Pro Subscription
1 month ago
+3.55%
Mesoblast shares are trading higher after the company secured a 7-year FDA orphan-drug exclusivity for Ryoncil in steroid-refractory pediatric graft versus host disease.
